Skip to main content
. 2020 Sep 15;4(12):1851–1863. doi: 10.1002/hep4.1597

FIG. 6.

FIG. 6

miR‐125b‐5p enhances proliferation of primary human hepatocytes. (A) qRT‐PCR of ABTB1 in human hepatocytes transfected with miR‐125b‐5p mimic or inhibitor. (B) Western blot of ABTB1 and its quantification in primary human hepatocytes transfected with miR‐125b‐5p mimic, inhibitor, or scramble control. (C) Luciferase reporter assay of human 3′ UTR ABTB1 in the presence of either miR‐125b‐5p mimic or inhibitor. (D) WST‐1 assay of primary human hepatocytes transfected with miR‐125b‐5p mimic, inhibitor, or scramble control. (E) Ki67 immunofluorescence staining of primary human hepatocytes transfected with miR‐125b‐5p mimic, inhibitor, or scramble control and its quantification. (F) Western blot for human ABTB1 and its quantification on lysates of primary human hepatocytes transfected with either siRNA targeting human ABTB1 or miR‐125b‐5p inhibitor. (G) Ki67 immunofluorescence staining of primary human hepatocytes transfected with siRNA alone or siRNA and miR‐125b‐5p inhibitor and its quantification. Scale bars, 200 μm. (H,I) qRT‐PCR analysis of (H) FOXG1 and (I) CDKN1A expression in primary human hepatocytes transfected with miR‐125b‐5p mimic, inhibitor, or ABTB1 siRNA. *P < 0.05, **P < 0.01; data are presented as mean ± SEM (n = 4 per group). Abbreviation: CDKN1A, cyclin‐dependent kinase inhibitor 1A.